Erica Ferrell, NP
Psychiatric/Mental Health · Hastings, NENPI 1770793838
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 478 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations.
Across 478 payments — averaging $12.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Alkermes, Inc.$998
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$874
- Otsuka America Pharmaceutical, Inc.$817
- Johnson & Johnson$480
- Neurocrine Biosciences, Inc.$337
- plus $1K from 18 others
What the payments were for
- Food & beverage$6,174100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 114 | $1,326 |
| Alkermes, Inc. | 101 | $998 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 49 | $874 |
| Otsuka America Pharmaceutical, Inc. | 58 | $817 |
| Johnson & Johnson | 53 | $480 |
| Neurocrine Biosciences, Inc. | 22 | $337 |
| Teva Pharmaceuticals USA, Inc. | 10 | $189 |
| Axsome Therapeutics, Inc. | 11 | $186 |
| Lundbeck LLC | 10 | $165 |
| Sunovion Pharmaceuticals Inc. | 12 | $152 |
| Ironshore Pharmaceuticals Inc. | 7 | $116 |
| E.r. Squibb & Sons, L.L.C. | 4 | $75 |
| Vanda Pharmaceuticals Inc. | 4 | $62 |
| Corium, LLC | 5 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $57 |
| Organogenesis Inc. | 2 | $55 |
| Collegium Pharmaceutical, Inc. | 2 | $45 |
| Indivior Inc. | 3 | $43 |
| Harmony Biosciences LLC | 2 | $37 |
| Biogen | 1 | $30 |
| Gilead | 1 | $22 |
| Tris Pharma Inc | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Bausch Health US, LLC | 1 | $13 |
How this compares
$6,174 in reported general payments places this provider in the 85th percentile of 255 psychiatric/mental health providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 54 | $324,084 |
| AustedoDeutetrabenazine | 19 | $234,643 |
| VraylarCariprazine Hcl | 116 | $145,849 |
| Austedo XrDeutetrabenazine | 21 | $130,654 |
| Invega SustennaPaliperidone Palmitate | 25 | $75,818 |
| TrintellixVortioxetine Hydrobromide | 76 | $40,511 |
| Abilify MaintenaAripiprazole | 14 | $39,964 |
| LybalviOlanzapine/Samidorphan Malate | 21 | $21,986 |
| CaplytaLumateperone Tosylate | 11 | $21,066 |
| AuvelityDextromethorphan Hbr/Bupropion | 18 | $10,624 |
| Clozapine | 137 | $10,108 |
| Divalproex Sodium | 61 | $5,546 |
| Paliperidone ErPaliperidone | 49 | $5,514 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 107 | $4,735 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,550 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $189 | $365,29640 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $337 | $324,08454 claims |
| AbbVieVraylar | $1,326 | $145,849116 claims |
| Johnson & JohnsonInvega Sustenna | $480 | $75,81825 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $57 | $45,06288 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $817 | $39,96414 claims |
| Alkermes, Inc.Lybalvi | $998 | $21,98621 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $874 | $21,06611 claims |
| Axsome Therapeutics, Inc.Auvelity | $186 | $10,62418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 255 psychiatric/mental health providers in Nebraska.
Other psychiatric/mental health in Hastings
- Dacia OakesonHastings$32K
- Suzanne GreggHastings$11K
- Margaret Emersonla Vista$30K
- Janelle HillOmaha$24K
- Kristi BoseOmaha$13K
- Robert LundholmOmaha$12K
- Sherry KropatschGrand Island$11K
- Virginia SmithOmaha$11K
- Christina HadleyOmaha$11K
- Helen TrotterLincoln$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.